Option chain shows key data for Scinai Immunotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Scinai Immunotherapeutics.

Scinai Immunotherapeutics (NASDAQ:SCNI) Stock, Option Chain

Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

ADTX

ADVM

AEHR

ALLR

AMIX

APVO

ASLN

ASML

ASST

CLIR

CRDO

CYCN

FDMT

FIVE

FUBO

GPCR

GTLB

HNST

JBHT

LAZR

LCFY

NAAS

NVDA

NVMI

OCTO

ONTO

QCOM

SAVA

SAVE

SCNI

SHIM

SIEB

SMTC

SNAP

SONM

TKNO

VKTX

VRPX

Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Crude Oil 6- logo

Eurozone

Commodities

LXEO

VTAK

Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results

Image49

AEON

AGRI

AREB

ASTL

COIN

DATS

EAST

FSLR

FUFU

HUMA

INOD

KZIA

LCID

MIRA

MLEC

MSTR

NOVA

PETZ

POWW

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SEDG

SQNS

TSLA

UPST

Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics Ltd

Press Releases

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Small Cap

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Earnings

Scinai Announces Annual Financial Results for 2024

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Aditxt

Alzamend Neuro

Aptevo Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

NuCana

Oragenics

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Comments

Scinai Immunotherapeutics

Scinai Immunotherapeutics (SCNI) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell